This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Belkowski, L S Articles by Sen, G C Search for Related Content PubMed PubMed Citation Articles by Belkowski, L S Articles by Sen, G C

 Previous Article  |  Next Article 

J Virol. 1987 March; 61(3): 653-660

Inhibition of vesicular stomatitis viral mRNA synthesis by interferons.

ABSTRACT

Interferon (IFN) treatment inhibited the replication of vesicular stomatitis virus (VSV) in human GM2767 and mouse JLSV-11 cells. The replication of this virus in either human RD-114 or mouse A402 cells was insensitive to IFN treatment. We analyzed various steps in the VSV life cycle as they occurred under different conditions of IFN treatment to identify the point(s) at which IFN was exerting its inhibitory effect. IFN treatment led to strong inhibition of viral protein synthesis and accumulation of viral RNA in both lines of IFN-sensitive cells. No such effect was observed in the IFN-resistant cells. Using a temperature-sensitive mutant (tsG41) and wild-type VSV that were not undergoing protein synthesis, we determined that the major site of action of IFN against VSV replication in JLSV-11 and GM2767 cells was at the level of primary viral transcription. The accumulation of primary viral transcripts was strongly inhibited in these cells by IFN treatment. This effect was not a consequence of any effect of IFN on virus entry and uncoating. Thus, it appears that IFN exerts a direct effect on the VSV transcriptional process in GM2767 and JLSV-11 cells.

This article has been cited by other articles:

• Basu, M., Maitra, R. K., Xiang, Y., Meng, X., Banerjee, A. K., Bose, S. (2006). Inhibition of vesicular stomatitis virus infection in epithelial cells by alpha interferon-induced soluble secreted proteins. J. Gen. Virol. 87: 2653-2662 [Abstract] [Full Text]  
• Shinozaki, K., Ebert, O., Suriawinata, A., Thung, S. N., Woo, S. L. C. (2005). Prophylactic Alpha Interferon Treatment Increases the Therapeutic Index of Oncolytic Vesicular Stomatitis Virus Virotherapy for Advanced Hepatocellular Carcinoma in Immune-Competent Rats. J. Virol. 79: 13705-13713 [Abstract] [Full Text]  
• Dong, B., Zhou, Q., Zhao, J., Zhou, A., Harty, R. N., Bose, S., Banerjee, A., Slee, R., Guenther, J., Williams, B. R. G., Wiedmer, T., Sims, P. J., Silverman, R. H. (2004). Phospholipid Scramblase 1 Potentiates the Antiviral Activity of Interferon. J. Virol. 78: 8983-8993 [Abstract] [Full Text]  
• Nishio, M., Tsurudome, M., Ito, M., Kawano, M., Komada, H., Ito, Y. (2001). High Resistance of Human Parainfluenza Type 2 Virus Protein-Expressing Cells to the Antiviral and Anti-Cell Proliferative Activities of Alpha/Beta Interferons: Cysteine-Rich V-Specific Domain Is Required for High Resistance to the Interferons. J. Virol. 75: 9165-9176 [Abstract] [Full Text]